Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06930664 · ClinicalTrials.gov registry record · Phase 1
A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 146
- Enrollment target
NCT06930664 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 146 participants.
The verdict
NCT06930664, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 146 participants
- Enrollment target
Study Summary
The goal of the study is to learn what happens to different forms of sotatercept medications in a healthy person's body over time. Researchers want to know if there is a difference in the healthy person's body when different forms of sotatercept medications are given.
Interventions
- BIOLOGICAL Sotatercept
- BIOLOGICAL Sotatercept Autoinjector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2025-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06930664
The ClinicalTrials.gov registry entry for NCT06930664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sotatercept is the first listed.
NCT06930664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06930664 about?
NCT06930664 is a clinical study titled "A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)". The goal of the study is to learn what happens to different forms of sotatercept medications in a healthy person's body over time. Researchers want to know if there is a difference in the healthy person's body when different forms of sotatercept medications are given.
What is the current status of trial NCT06930664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 146 participants. The study started on 2025-05-16. Estimated completion is 2025-11-25.
What interventions are being tested in trial NCT06930664?
The interventions under investigation include: Sotatercept (BIOLOGICAL), Sotatercept Autoinjector (BIOLOGICAL).
Who is sponsoring clinical trial NCT06930664?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.